Wilson, Mfool, Morning star and many other says lots of thing and they are as prone to error on their judgement as others except when when they got internal information leaked... IMO.
I don't have any concerns on duration for trial as long as private patients start using it and shows effectiveness similar or better to the assessment in above article... IMO.
New CEO certainly has something under his sleeve that previously not considered in term of marketing development and sales ... IMO... so stay optimistic and hopefully things will work out different to what happened in past decade under new management... and always invest with exit strategy... IMO.
OSL Price at posting:
9.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)